5-Amino-1MQ — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

5-Amino-1MQ

Also known as: 5-amino-1-methylquinolinium, 5-amino-1-methylquinolinium iodide, 5MQ, NNMTi

Small molecule NNMT (nicotinamide N-methyltransferase) inhibitor; quinolinium compound

Research chemicalLast updated: November 4, 2026Based on 3 peer-reviewed studiesPreclinical data only — no human trials

What it is

5-Amino-1MQ is a compound people use for fat loss and metabolic support. It works by blocking an enzyme that controls how the body stores energy. Research is mostly in animals, with early interest in obesity, gut health, and some cancers. No FDA-approved use.

The scientific side

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), a cytosolic metabolic enzyme involved in NAD metabolism. By inhibiting NNMT, it modulates downstream pathways relevant to tumor progression, metabolic regulation, and immune response. In cancer-associated fibroblasts (CAFs) in urothelial bladder cancer (UBC), NNMT drives tumor progression by epigenetically reprogramming serum amyloid A (SAA) expression to recruit and differentiate tumor-associated macrophages; targeting NNMT with 5-amino-1-methylquinolinium iodide reduced tumor growth and enhanced apoptotic effects of anti-PD-L1 antibody in mouse models. In diet-induced obese (DIO) mice, NNMT inhibition combined with low-fat diet promoted whole-body adiposity and weight loss, normalizing these measures to age-matched lean controls, and was associated with distinct gut microbiome changes including decreased Erysipelatoclostridium and increased Lactobacillus. In vitro, 5MQ inhibited HeLa cervical cancer cell proliferation in a concentration- and time-dependent manner, reduced phospho-Akt and SIRT1 protein expression, and was associated with morphological signs of apoptosis, without apparently affecting HEK-293 (non-cancer) cell proliferation.

Class: Small molecule NNMT (nicotinamide N-methyltransferase) inhibitor; quinolinium compound

Administration & storage

Cautions
No human pharmacokinetic or safety data are reported in the reviewed abstracts.,All in vivo efficacy data are from mouse models only; translation to human use is not established.,Dose, route, and duration of administration in animal studies were not quantitatively specified in the reviewed abstracts, limiting any dose-guidance inferences.,Sterile technique should always be observed when preparing injectable compounds; this is a universal harm-reduction principle not specific to 5-Amino-1MQ.,Formulation purity and pharmaceutical-grade sourcing are not addressed in the reviewed abstracts — quality cannot be assumed for non-pharmaceutical preparations.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification